• # LGM Pharma is a Diclofenac Sodium CAS# 15307-79-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Diclofenac Sodium
  • CAS #: 15307-79-6
  • Mode of Action:

    The antiinflammatory effects of diclofenac are believed to be due to inhibition of both leukocyte migration and the enzyme cylooxygenase (COX-1 and COX-2), leading to the peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis is responsible for the analgesic effects of diclofenac. Antipyretic effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat dissipation.

  • Pharmacodynamics:

    Diclofenac is an acetic acid nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Diclofenac is used to treat pain, dysmenorrhea, ocular inflammation, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and actinic keratosis

  • Toxicity:

    Symptoms of overdose include loss of consciousness, increased intracranial pressure, and aspiration pneumonitis. LD50=390mg/kg (orally in mice)

  • IUPAC: Acetic acid, o-(2, 6-dichloroanilino)phenyl-, monosodium salt, Benzeneacetic acid, 2-((2, 6-dichlorophenyl)amino)-, monosodium salt, Feloran, Sodium (2-((2, 6-dichlorophenyl)amino)phenyl)acetate
  • ATC: M01AB05" M02AA15" S01BC03" D11AX18
  • PubChem: 3033
  • DrugBank: APRD00527
  • Formula: C14 H11 N1 O2
  • Molecular Mass: 318.134
  • Synonyms: (o-(2,6-Dichloroanilino)phenyl)acetic acid monosodium salt, (o-(2,6-Dichloroanilino)phenyl)acetic acid sodium salt, 2-((2,6-Dichlorophenyl)amino)benzeneacetic acid monosodium salt, Abitren, Allvoran, Anthraxiton, Assaren, Ba 47210, Batafil, Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, monosodium salt, Blesin, CCRIS 1909, Delimon, Delphimix, DIC075V, Dichronic, Diclofenac sodium, Diclofenac sodium topical gel, Diclophenac sodium, EINECS 239-346-4, GP 45840, Kriplex, Neriodin, Orthophen, Ortofen, Pennsaid, Prophenatin, Sodium (o-((2,6-dichlorophenyl)amino)phenyl)acetate, Sodium (o-(2,6-dichloroanilino)phenyl) acetate, Sodium (o-(2,6-dichloroanilino)phenyl)acetate, Sodium diclofenac, Solaraze, Tsudohmin, UNII-QTG126297Q, Urigon, Valetan, Voltaren, Voltaren Gel, Voltaren ophthalmic, Voltaren-XR, Voltarene, Voltarol, Vonafec, Vurdon
  • AHFS Code: 28:08.04.92, 28:08.04.08
  • General Reference:


    1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006 Jun 3;332(7553):1302-8. Pubmed
    2. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S: Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May;54(5):1378-89. Pubmed
    3. FitzGerald GA, Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001 Aug 9;345(6):433-42. Pubmed
    4. Graham DJ: COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006 Oct 4;296(13):1653-6. Epub 2006 Sep 12. Pubmed
    5. Brater DC: Renal effects of cyclooxygyenase-2-selective inhibitors. J Pain Symptom Manage. 2002 Apr;23(4 Suppl):S15-20; discussion S21-3. Pubmed
    6. Sigma Aldrich Link
    7. Gan TJ: Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010 Jul;26(7):1715-31. Pubmed


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service